Navigation Links
Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
Date:7/23/2013

technology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at  www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to his
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
2. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
3. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
4. Generex Announces Date of Annual Stockholders Meeting
5. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Secures Commitments for $3.6M Capital Raise
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
10. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... disease remains a challenge in management. With ... in the seven major markets of the ...
(Date:5/28/2015)... Research and Markets ... of Jain PharmaBiotech,s new report "Therapeutic ... to their offering.      ... deals with therapeutic drug monitoring, a multi-disciplinary ... by monitoring drug levels in the blood ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Therapeutic Drug Monitoring Market 2015-2024 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3
... from Phase II Study Evaluating Bavituximab in Advanced ... from Phase I Study Evaluating Bavituximab in Multiple ... Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical ... treatment of cancer and serious virus infections, today ...
... The atherosclerosis vaccine,development program by AFFiRiS AG ... The respective project is being carried out in,cooperation ... of,atherosclerosis vaccination is to increase the amount of ... and thus reduce the occurrence of,harmful fatty deposits ...
... to Drive Production Efficiency and Manage Quality at New ... 27 Honeywell (NYSE: HON ) today ... a leading global manufacturer of healthcare products, to provide ... produce clinical nutrition and infusion therapy solutions. The Leading ...
Cached Biology Technology:Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... The Lupus Research Institute (LRI) strategy of backing innovative ... yielded an unprecedented $30 million in large-scale funding from ... private sources, an independent progress report has determined. ... novel research grants from the 7-year-old LRIan Institute investment ...
... increase depth and breadth of coverage, applicability and usefulness ... Information Facility (GBIF) has set a goal of making ... its data portal by December 2008., GBIF calls on ... digitising and sharing their data to deepen and broaden ...
... big dividends to aging baby boomers who want to stay ... geriatric medicine at Saint Louis University, in a new book ... as we age. Living well and feeling good enough ... is priceless, says Morley, who is coauthor of The Science ...
Cached Biology News:Lupus Research Institute strategy delivers $30 million in national funding 2GBIF sets goal of mobilizing 1 billion records by end of 2008 2Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 2Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 3Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 4
... AmpliTaq Gold® DNA Polymerase is a ... When the chemical moiety is attached to ... set-up and the first ramp of thermal ... non-optimal annealing temperatures), the enzyme is inactive. ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: